Considering the personal, societal, and economic toll of treatment-resistant depression, we must make it easier to access medicines and care that provide value, both for the patient and for the health care system.
Kruti Joshi, MPH
Advertisement
Kruti Joshi, MPH, Director, Real World Value & Evidence, Janssen Pharmaceuticals, Inc.
Articles by Kruti Joshi, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
3
Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups
4
SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF
5